skip to Main Content

Drug Pricing

Keep up with our comprehensive coverage of administrative and legislative activity and what it means for industry, plans, providers, and patients.

Podcast: E1 – Specialty Pharmacy Stakeholder Perspectives: Specialty Pharmacy Outlook

In the first episode of the Specialty Pharmacy Stakeholder Perspectives series, Avalere is joined by Joel Wright, CEO at AllianceRx and Ernie Shopes, SVP Products and Client Delivery at Creehan and Company, discussing the outlook for specialty pharmacy, including a focus on trends in the pipeline and overall landscape.

What’s Next for Medicaid Drug Pricing?

On February 27, Avalere experts discussed the latest policy, pricing, and reimbursement challenges for prescription drugs in Medicaid in the “What’s Next for Medicaid Drug Pricing?” webinar. They reviewed the ways prescription drugs are managed in Medicaid, what innovative medicines may mean for the program, and potential implications of CMS’ Healthy Adult Opportunity (HAO).

Podcast: E2 – Avalere Insights on Recent CMS Proposed Payment Rules: MPFS

Tune in to hear the second episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 2, we’ll be focusing on the Medicare Physician Fee Schedule proposed rule, or MPFS, with a focus on proposed changes to E/M and Opioid Use Disorder (OUD) treatment services.

Brigit Kyei-Baffour

Podcast: E1 – Avalere Insights on Recent CMS Proposed Payment Rules: OPPS

Tune in to hear the first episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 1, we’ll be focusing on the outpatient prospective payment system proposed rule, more informally known as the OPPS.

HHS Proposes to Remove Safe Harbor for Drug Manufacturer Rebates

Yesterday, the Department of Health and Human Services Office of Inspector General released a proposed rule redefining the current safe harbor for pharmaceutical manufacturer discounts and rebates to entities like health plans and pharmacy benefit managers (PBMs).

Post-Election, Part B Drug Reform Is Likely to Advance

Avalere analysis finds that most of the payment reductions from the proposed International Pricing Index Model for Part B drugs would affect oncologists, rheumatologists, and ophthalmologists.

Drug Pricing Webinar Image

Webinar: Drug Pricing Policy: What’s on the Horizon?

Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.

Sign up to receive more insights about Drug Pricing
Please enter your email address to be notified when new Drug Pricing insights are published.

Back To Top